Skip to main content

Table 1 Baseline patients characteristics

From: Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

Parameter (units) Safety population (N = 126) ITT population (N = 125) PP population (N = 116)
Age (years), mean ± SD 68.75 ± 8.64 68.65 ± 8.61 68.69 ± 8.61
Height (cm), mean ± SD 159.91 ± 9.72 160.11 ± 9.50 159.97 ± 9.34
Weight (kg), mean ± SD 63.52 ± 9.90 63.60 ± 9.90 63.45 ± 9.54
BMI (kg/m2), mean ± SD 24.94 ± 4.16 24.91 ± 4.15 24.90 ± 4.11
Gender, n (%)
 Female 35 (27.78) 35 (28) 32 (27.59)
 Male 91 (72.22) 90 (72) 84 (72.41)
Study eye, n (%)
 Left 51 (40.48) 50 (40) 46 (39.66)
 Right 75 (59.52) 75 (60) 70 (60.34)
  1. BMI body mass index, ITT intent-to-treat, PP per-protocol, SD standard deviation